Status:

WITHDRAWN

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Conditions:

HIV Infections

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to determine the safety, tolerability, and plasma pharmacokinetics (i.e., the levels of TMC589337 and TMC589354 circulating in your blood over time) of increasing single or...

Detailed Description

This is a First-in-Human Phase I, double-blind (neither physician or patient knows the name of the assigned study drug), randomized (study medication assigned by chance), placebo-controlled (a group o...

Eligibility Criteria

Inclusion

  • Nonsmokers for at least 3 months prior to selection
  • Weight as defined by a Body Mass Index (BMI, weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2, extremes included
  • Informed Consent Form (ICF) signed voluntarily
  • Able to comply with protocol requirements
  • Healthy on the basis of a pretrial physical examination, medical history, the results of blood biochemistry and hematology tests, a urinalysis, vital signs, and a 12-lead electrocardiogram (ECG).

Exclusion

  • Past history of clinically significant heart arrhythmias (extrasystolic, tachycardia at rest)
  • having baseline prolongation of QTc interval \> 450 ms, history of risk factors for Torsade de Pointes syndrome (hypokalemia, family history of long QT Syndrome)
  • Female, except if postmenopausal for more than 2 years, or posthysterectomy or postsurgical sterilization (without reversal operation)
  • Currently active clinically relevant or significant underlying gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease
  • History of clinically relevant skin disease or allergy including drug allergy as well.

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2009

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00908414

Start Date

May 1 2009

End Date

October 1 2009

Last Update

October 28 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Utrecht, Netherlands